bioteNASDAQ: BTMD

biote Corp. (BTMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a binding term sheet with Marci M. Donovitz, stockholder of Biote, to resolve litigation (“Donovitz Litigation”). For $60 million in the aggregate, Biote will repurchase all of the approximately 8.3 million of the Paired Interests and/or Class.

Biote Corp. (BTMD) lacks the necessary ingredients for a potential earnings beat in its upcoming report. Be ready for the key expectations.

biote Corp. (BTMD) Q4 2023 Earnings Call Transcript

Biote Corp. (BTMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and its expansion into complementary wellness products. BTMD is considered undervalued and has an aggressive price target for the end of next year.

Biote Corp. (BTMD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.08. This compares to loss of $0.09 per share a year ago.

If you are looking for stocks that are well positioned to maintain their recent uptrend, biote Corp. (BTMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

biote Corp. (BTMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.